In the past week, LYRA stock has gone down by -12.27%, with a monthly decline of -22.50% and a quarterly plunge of -12.65%. The volatility ratio for the week is 8.33%, and the volatility levels for the last 30 days are 7.75% for Lyra Therapeutics Inc. The simple moving average for the past 20 days is -15.14% for LYRA’s stock, with a -34.54% simple moving average for the past 200 days.
Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?
The 36-month beta value for LYRA is also noteworthy at -0.04. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for LYRA is 54.86M, and at present, short sellers hold a 3.42% of that float. The average trading volume of LYRA on March 19, 2025 was 1.23M shares.
LYRA) stock’s latest price update
Lyra Therapeutics Inc (NASDAQ: LYRA)’s stock price has gone decline by -0.06 in comparison to its previous close of 0.16, however, the company has experienced a -12.27% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-13 that WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at -16.60% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.65% of loss for the given period.
Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 8.33%, as shares sank -18.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.08% lower at present.
During the last 5 trading sessions, LYRA fell by -11.99%, which changed the moving average for the period of 200-days by -51.75% in comparison to the 20-day moving average, which settled at $0.1880. In addition, Lyra Therapeutics Inc saw -22.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -62.81 for the present operating margin
- -7.74 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -60.91. The total capital return value is set at -1.79. Equity return is now at value -184.99, with -89.43 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -2.04.
Currently, EBITDA for the company is -96.35 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 2.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.41.
Conclusion
In summary, Lyra Therapeutics Inc (LYRA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
